Copyright ©  1991-2017   Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.,  All Rights Reserved.


Welcome to Beijing Wantai
Manufacturer of Infectious Diseases Diagnostics

Wantai is a Global Leader in Hepatitis E Diagnostics

Immunoshop India Pvt. Ltd. (India)
Eurobio (France, Switzerland)
Sanbio (Benelux countries, Germany)
DBA Italia (Italy)
Quilaban (Portugal)
Nordic BioSite AB (Sweden, Denmark, Norway and Finland)
SZABO-SCANDIC HandelsgmbH & Co KG (Austria)
Dow Biomedica Inc (South Korea)
Copernicus Diagnostics (Poland)
HyLabs (Israel)
                    
Other countries availability:

SZABO-SCANDIC HandelsgmbH & Co KG

Hungary, Czech Republic, Slovakia, Slovenia, Serbia, Bosnia, Croatia


Nordic BioSite AB Estonia, Latvia, Lithuania

Catalog No.
  Product
Brochure
Certification
IFU
WE-7196
HEV-IgM ELISA
CE
WE-7296
HEV-IgG ELISA
CE
WE-7396
HEV-Ab ELISA
 
WE-7596
HEV-Ag ELISA
CE
WJ-1510 HEV IgM Rapid Test
CE
What is Hepatitis E?

Hepatitis E is caused by infection with hepatitis E virus (HEV). Hepatitis E is a waterborne disease and contaminated water or food supplies from a single source can lead to major outbreaks in developing countries.

HEV causes acute sporadic and epidemic viral hepatitis. Symptomatic HEV infection is most common in adults aged 15-40 years. Occasionally, a severe form of hepatitis develops, with mortality rates ranging between 0.5% - 4.0% of the overall population. This severe form of hepatitis may reach a mortality rate of 20% during pregnancy in the 3rd trimester.

HEV in blood donors


While HEV transmission usually occurs by eating and drinking contaminated food and water, blood transfusion is another route of infection.In a study conducted with 44,816 donor samples were collected in China between 2002 to 2008, the HEV seroprevalences in blood donors ranged from 29.9% to 41.7%. The rate of acute HEV infection was 0.43% to 1.51%. The viremia rates among the donors in 6 different regions of China ranged from 0.02% to 0.14%. These results also showed a high prevalence of viremia among anti-HEV IgM-positive samples.  A total of 7.14% (30/420) of anti-HEV IgM-positive samples were RNA positive, but none of the IgM-negative samples were HEV RNA positive.

Recent seroprevalence studies indicate high prevalence of HEV infection among healthy populations in some industrial countries with historically low occurrence of Hepatitis E including the US, Japan and Europe.

Hepatitis E Vaccine :
Hecolin®



Generic name: Recombinant Hepatitis E Vaccine (Escherichia Coli)
Trade name: Hecolin® (Hecolin®)

This product is suitable for susceptible population aged 16 and above. It is recommended for individuals exposed to high risk of hepatitis E virus infection, such as those engaged in animal husbandry, those engaged in catering, students, officers and soldiers, women of childbearing age, travelers to endemic areas and so on.

Indications and Usage:
Inoculation of this product can stimulate the body to produce immunity against hepatitis E virus for the prevention of hepatitis E.


For more information, please contact our sister company INNOVAX

Add:130 Xinyuan Road, Haicang , Xiamen, China, P.C.: 361022
Tel:+86-592-6536555, Fax:+86-592-6536567
www.innovax.cn



Global News on Hepatitis E


[05-25-2017] WHO Weekly Bulletin: Update on the ongoing HEV outbreak in Niger and Chad

[05-08-2017] WHO: update on a recent HEV outbreak in Niger

[04-27-2017] MSF: "Niger: Hepatitis E outbreak linked to water shortages and poor sanitation

[04-20-2017] Niger reports hepatitis E outbreak in Diffa region

[02-10-2017] The Lancet Gastroenterology & hepatology: “Hepatitis E: urgent action needed”

[12-26-2016] MSF: The End of Viral Hepatitis by 2030 is Impossible without Tackling Hep.E




 




hev map
HEV
HIV
HTLV
HBV
HCV
EV-71
SYPHILIS
TB-IGRA